According to a new report Europe Meningococcal Vaccine Market, published by KBV research, the Europe Meningococcal Vaccine Market would witness market growth of 8% CAGR during the forecast period (2020-2026).
The Germany market dominated the Europe Quadrivalent Market by Country in 2019, growing at a CAGR of 7 % during the forecast period. The UK market is experiencing a CAGR of 6.7% during (2020 - 2026). Additionally, The France market is poised to witness a CAGR of 9.1% during (2020 - 2026).
The Children (2 years & above) and Adults market dominated the Russia Meningococcal Vaccine Market by Age Group in 2019, growing at a CAGR of 7.9 % during the forecast period. The Infants (0 to 2 years) market is estimated to grow at a CAGR of 10.6% during (2020 - 2026).
The Bexsero market dominated the Italy Meningococcal Vaccine Market by Brand in 2019, thereby, achieving a market value of $16.6 Million by 202. The Trumenba market is exhibiting a CAGR of 8.9% during (2020 - 2026).
Full Report: https://www.kbvresearch.com/europe-meningococcal-vaccine-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
By Brand
By Type
By Age Group
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
